Get the Stockscreener App
0.5997
3.62%
-0.0028
Xortx Therapeutics Inc stock is traded at $0.5997, with a volume of 96,883.
It is down -3.62% in the last 24 hours and down -27.41% over the past month.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$0.6025
Open:
$0.61
24h Volume:
96,883
Relative Volume:
0.05
Market Cap:
$3.03M
Revenue:
-
Net Income/Loss:
$-736.70K
P/E Ratio:
-59.97
EPS:
-0.01
Net Cash Flow:
$-4.14M
1W Performance:
-12.35%
1M Performance:
-27.41%
6M Performance:
-42.50%
1Y Performance:
-59.39%
1-Day Range:
$0.5725
$0.6174
1-Week Range:
$0.5725
$0.73
52-Week Range:
$0.5725
$1.79
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.5807 | 3.49M | 0 | -736.70K | -4.14M | -0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.00 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.70 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.76 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.09 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
Heatmap analysis for XORTX Therapeutics Inc. and competitorsJuly 2025 WrapUp & Free Long-Term Investment Growth Plans - newser.com
Is XORTX Therapeutics Inc. stock cheap at current valuation2025 Technical Overview & Safe Capital Growth Tips - newser.com
Statistical indicators supporting XORTX Therapeutics Inc.’s strengthJuly 2025 Volume & Technical Entry and Exit Tips - newser.com
Can XORTX Therapeutics Inc. stock sustain revenue growthProduct Launch & Safe Entry Trade Signal Reports - newser.com
What data driven models say about XORTX Therapeutics Inc.’s futureWeekly Trade Recap & Verified Swing Trading Watchlists - newser.com
How XORTX Therapeutics Inc. (ANUA) stock reacts to stronger dollar2025 Technical Patterns & Risk Adjusted Swing Trade Ideas - newser.com
Is XORTX Therapeutics Inc. stock entering bullish territoryIPO Watch & Target Return Focused Stock Picks - newser.com
Can XORTX Therapeutics Inc. stock attract ESG capital inflowsPortfolio Gains Summary & Safe Capital Growth Trade Ideas - newser.com
XORTX Therapeutics Completes $1.1 Million Direct Offering - MSN
Is XORTX Therapeutics Inc. forming a bottoming baseJuly 2025 Patterns & Community Supported Trade Ideas - newser.com
Is XORTX Therapeutics Inc. trending in predictive chart modelsEarnings Trend Report & Stepwise Trade Execution Plans - newser.com
Will XORTX Therapeutics Inc. stock see insider buyingJuly 2025 Price Swings & Weekly Breakout Stock Alerts - newser.com
Predicting XORTX Therapeutics Inc. trend using moving averages2025 Technical Overview & Reliable Breakout Forecasts - newser.com
Will XORTX Therapeutics Inc. bounce back from current support2025 Retail Activity & Target Return Focused Stock Picks - newser.com
Will XORTX Therapeutics Inc. stock gain from government policiesMarket Performance Recap & Weekly Stock Performance Updates - newser.com
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN
Order flow analysis tools used on XORTX Therapeutics Inc.Bull Run & Entry Point Confirmation Alerts - newser.com
Can XORTX Therapeutics Inc. stock reach $100 price targetMarket Sentiment Review & Free Safe Entry Trade Signal Reports - newser.com
Is XORTX Therapeutics Inc. (ANUA) stock attractive for growth funds2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
Can XORTX Therapeutics Inc. (ANUA) stock beat analyst consensusJuly 2025 Trends & Stepwise Trade Signal Implementation - newser.com
How to build a custom watchlist for XORTX Therapeutics Inc.Quarterly Trade Summary & Fast Entry High Yield Tips - newser.com
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
XORTX Therapeutics Inc Stock Analysis and ForecastAnalyst Downgrades & Get Tomorrow’s Winners Today With AI - earlytimes.in
Vectus Biosystems Advances Strategic Partnerships and Licensing Opportunities - TipRanks
XORTX Therapeutics files to sell up to 4.76M shares - MSN
[6-K] XORTX Therapeutics Inc. Current Report (Foreign Issuer) - Stock Titan
Will XORTX Therapeutics Inc. stock maintain momentum in 2025Insider Buying & Low Risk Entry Point Guides - newser.com
XORTX Therapeutics Secures $1.1 Million in Direct Offering - TipRanks
XORTX Therapeutics Brief: Closed US$1.1 Million Registered Direct Offering - MarketScreener
XORTX Announces Closing of US$1.1 Million Registered Direct Offering - The Manila Times
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):